We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
- Authors
Zhang, Xu-chao; Cao, Xu; Sun, Chun; Xie, Zhi; Guo, Jian-jun; Yang, Jin-ji; Yang, Xue-ning; Dai, Hang-jun; Li, Su-chun; Xu, Xin-ran; Zuo, Yun-xia; Chen, Meng; Koeppen, Hartmut; He, Jing; Kiermaier, Astrid; Shames, David; Cheng, Gang; Wu, Yi-long
- Abstract
The goal of this study is to evaluate PD-L1 prevalence and its association with major clinical characteristics in Chinese non-small cell lung cancer (NSCLC) patients to inform the clinical development of anti-PD1/PD-L1 agents in this population. We used phosphatase and tensin homolog (PTEN) expression through IHC as a surrogate tissue quality marker to screen surgical NSCLC samples in tissue microarray (TMA; 172 cases) or whole-section (268 cases) format. The samples were then analyzed with a clinically validated PD-L1 IHC assay. The results were correlated with baseline characteristics and clinical outcomes. PTEN IHC showed that 108 TMA samples and 105 whole-section samples qualified for PD-L1 IHC. With a clinically relevant cutoff, 41.7% of the TMA samples were PD-L1 positive. PD-L1 level was much lower in EGFR-mutant patients and seemed to be a favorable prognostic factor for both overall survival (OS) and recurrence-free survival (RFS). These findings were confirmed in the whole-section samples except that their survival data were not mature enough for correlation analysis. In summary, PD-L1 expression was detected in approximately 40% of PTEN-qualified Chinese NSCLC samples, negatively correlated with EGFR mutation and seemed to be a favorable prognostic factor for both OS and RFS. Notably, the different results from PTEN-qualified and PTEN-disqualified samples underscore the importance of tissue quality control prior to biomarker testing.
- Subjects
CHILE; NON-small-cell lung carcinoma; PHOSPHATASES; PUBLIC health; MICROARRAY technology; HEALTH outcome assessment; PROGRESSION-free survival; PATIENTS
- Publication
Cancer Immunology, Immunotherapy, 2018, Vol 67, Issue 3, p471
- ISSN
0340-7004
- Publication type
Article
- DOI
10.1007/s00262-017-2098-4